Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
NRIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.90 - $29.56
Previous CloseN/A
Volume302.00K
Average Volume (3M)856.30K
Market Cap
$985.77M
Enterprise Value$1.15B
Total Cash (Recent Filing)$110.00M
Total Debt (Recent Filing)$28.30M
Price to Earnings (P/E)―
Beta2.65
Next Earnings
Apr 09, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.89
Shares Outstanding75,886,820
10 Day Avg. Volume1,081,881
30 Day Avg. Volume856,297
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.07
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit21.13
Enterprise Value/Ebitda-5.86
Forecast
1Y Price Target
$31.00Price Target Upside138.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Nurix Therapeutics News
PremiumCompany Announcements
Nurix Therapeutics Appoints Dr. Roy D. Baynes to Board
PremiumCompany Announcements
Nurix Therapeutics Faces Financial Risks Amid Supreme Court Regulatory ShiftPremiumCompany Announcements
Nurix Therapeutics Reports Solid Progress and Strong Pipeline
---
Bulls Say, Bears Say
Bulls Say
EarningsAnalyst reiterates a Buy rating, while slightly raising the 12-month price target to $36 from the prior $35.
Financial PerformanceThe company has significant cash reserves, which provide a financial runway for continued research and development efforts.
Bears Say
Clinical TrialsFailure to obtain timely approval for pipeline candidates, particularly NX-2127 and NX-5948, is a risk.
Market CompetitionNX-5948 faces fierce competition in the CLL market with major competitors also developing BTK degraders.
---
Ownership Overview
4.87% Insiders
27.21% Mutual Funds
6.13% Other Institutional Investors
45.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $11.90 and its highest was $29.56 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Nurix Therapeutics’s market cap is $985.77M.
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Apr 09, 2025 which is in 15 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Jan 28, 2025. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.686 by -$0.064.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -0.77.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 75,886,820 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.686. Following the earnings report the stock price went up 0.46%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Currently, no hedge funds are holding shares in NRIX
---
Nurix Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (138.65% Upside)
$31.00 (138.65% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 885.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.23%
12-Months-Change
Fundamentals
Return on Equity
-53.22%
Trailing 12-Months
Asset Growth
85.28%
Trailing 12-Months
Company Description
Nurix Therapeutics
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
---
NRIX Stock 12 Month Forecast
Average Price Target
$31.00
▲(138.65% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
CytomX Therapeutics
―
Rhythm Pharmaceuticals
―
Arvinas Holding Company
―
Best Analysts Covering NRIX
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
+37.69%
reiterated a buy rating 2 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +37.69% per trade.
---